CLINICAL_TRIALS
trial_result
· 2017-10-23
Clinical Trial Update: Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism [Phase 3]
Summary
Phase 3 trial evaluating the safety and efficacy of oral LPCN 1021 in men with low testosterone or hypogonadism has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Lipocine Inc. | Conditions: Male Hypogonadism | Phase 3 | Status: COMPLETED